Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$2.43
$0.10(4.59%)
At close: 4:00 PM EDT
$2.43
$0.10(4.59%)
Day’s Range― - ―
52-Week Range$1.61 - $6.88
Previous CloseN/A
Volume336.06K
Average Volume (3M)2.97M
Market Cap
$416.00M
Enterprise Value$238.84
Total Cash (Recent Filing)$179.88M
Total Debt (Recent Filing)$9.63M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding180,087,920
10 Day Avg. Volume2,375,753
30 Day Avg. Volume2,969,440
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.33Price Target Upside284.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ValidationPositive Phase 2/3 efficacy data strengthen the lead program’s development case and could improve the probability of regulatory progress, partnering interest, and eventual commercial adoption if the findings are confirmed.
Pipeline And Development RunwayA diversified pipeline and stated funding runway provide time to advance several clinical programs and reach important milestones, reducing immediate execution pressure compared with a single-asset company facing near-term financing needs.
Low Financial LeverageLow leverage and a substantial equity base give Compass greater financial flexibility to fund development and absorb operating volatility than a similarly loss-making biotech carrying significant debt obligations.
Bears Say
Persistent Losses And Minimal RevenueMinimal revenue provides little evidence of commercial traction, while widening operating losses show that research spending is not yet supported by recurring business income, leaving investment returns dependent on future clinical success.
Significant Ongoing Cash BurnSustained negative cash generation means Compass must continue relying on external financing or strategic transactions to fund trials, creating dilution and liquidity risk if development costs remain high.
Unproven Commercial ModelWithout an approved product or established recurring revenue stream, the company has not yet demonstrated commercial execution. Regulatory setbacks, trial delays, or weak uptake could materially defer or reduce future revenue.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.61 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $416.00M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 180,087,920 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 5.291%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (284.09% Upside)
$9.33 (284.09% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Compass Therapeutics
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$9.33
▲(284.09% Upside)
Technical Analysis
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.74% Insiders
7.09% Mutual Funds
50.49% Other Institutional Investors
16.70% Public Companies and
Individual Investors